Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M.

J Clin Invest. 2018 Sep 10. pii: 99317. doi: 10.1172/JCI99317. [Epub ahead of print]

2.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT, Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC, Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

3.

Use of Precision-Cut Lung Slices as an Ex Vivo Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy.

Rosales Gerpe MC, van Vloten JP, Santry LA, de Jong J, Mould RC, Pelin A, Bell JC, Bridle BW, Wootton SK.

Mol Ther Methods Clin Dev. 2018 Aug 4;10:245-256. doi: 10.1016/j.omtm.2018.07.010. eCollection 2018 Sep 21.

4.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS.

J Immunother Cancer. 2018 Jun 19;6(1):62. doi: 10.1186/s40425-018-0366-2.

5.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.

Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.

PMID:
29900060
6.

Gestation at birth, mode of birth, infant feeding and childhood hospitalization with infection.

Bentley JP, Burgner DP, Shand AW, Bell JC, Miller JE, Nassar N.

Acta Obstet Gynecol Scand. 2018 May 16. doi: 10.1111/aogs.13371. [Epub ahead of print]

PMID:
29768650
7.

Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy.

Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH.

Nat Rev Cancer. 2018 May 4. doi: 10.1038/s41568-018-0019-2. [Epub ahead of print]

PMID:
29728690
8.

Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.

Martin NT, Bell JC.

Mol Ther. 2018 Jun 6;26(6):1414-1422. doi: 10.1016/j.ymthe.2018.04.001. Epub 2018 Apr 5. Review.

PMID:
29703699
9.

Oncolytic viruses as engineering platforms for combination immunotherapy.

Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH.

Nat Rev Cancer. 2018 Jul;18(7):419-432. doi: 10.1038/s41568-018-0009-4. Review. Erratum in: Nat Rev Cancer. 2018 May 4;:.

PMID:
29695749
10.

Chromatin-associated RNA sequencing (ChAR-seq) maps genome-wide RNA-to-DNA contacts.

Bell JC, Jukam D, Teran NA, Risca VI, Smith OK, Johnson WL, Skotheim JM, Greenleaf WJ, Straight AF.

Elife. 2018 Apr 12;7. pii: e27024. doi: 10.7554/eLife.27024.

11.

Measurement of Mesoscale Conformational Dynamics of Freely Diffusing Molecules with Tracking FCS.

Limouse C, Bell JC, Fuller CJ, Straight AF, Mabuchi H.

Biophys J. 2018 Apr 10;114(7):1539-1550. doi: 10.1016/j.bpj.2018.01.044.

PMID:
29642025
12.

Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey.

Bell JC, Schneuer FJ, Harrison C, Trevena L, Hiscock H, Elshaug AG, Nassar N.

Arch Dis Child. 2018 Jul;103(7):660-664. doi: 10.1136/archdischild-2017-314161. Epub 2018 Feb 22.

PMID:
29472195
13.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

PMID:
29399408
14.

Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition.

Selman M, Ou P, Rousso C, Bergeron A, Krishnan R, Pikor L, Chen A, Keller BA, Ilkow C, Bell JC, Diallo JS.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaao1613. doi: 10.1126/scitranslmed.aao1613.

PMID:
29367345
15.

Accidental pharmacological poisonings in young children: population-based study in three settings.

Bell JC, Bentley JP, Downie C, Cairns R, Buckley NA, Katelaris A, Pearson SA, Nassar N.

Clin Toxicol (Phila). 2018 Aug;56(8):782-789. doi: 10.1080/15563650.2017.1422509. Epub 2018 Jan 15.

PMID:
29334809
16.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
17.

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC.

J Immunother. 2018 Apr;41(3):125-129. doi: 10.1097/CJI.0000000000000208.

18.

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM.

Cancer Res. 2018 Feb 15;78(4):922-937. doi: 10.1158/0008-5472.CAN-15-3308. Epub 2017 Dec 19.

PMID:
29259007
19.

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Selman M, Rousso C, Bergeron A, Son HH, Krishnan R, El-Sayes NA, Varette O, Chen A, Le Boeuf F, Tzelepis F, Bell JC, Crans DC, Diallo JS.

Mol Ther. 2018 Jan 3;26(1):56-69. doi: 10.1016/j.ymthe.2017.10.014. Epub 2017 Oct 24.

PMID:
29175158
20.

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.

Guo ZS, Liu Z, Sathaiah M, Wang J, Ravindranathan R, Kim E, Huang S, Kenniston TW, Bell JC, Zeh HJ 3rd, Butterfield LH, Gambotto A, Bartlett DL.

Mol Ther Methods Clin Dev. 2017 Sep 30;7:112-122. doi: 10.1016/j.omtm.2017.09.007. eCollection 2017 Dec 15.

21.

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.

Le Boeuf F, Gebremeskel S, McMullen N, He H, Greenshields AL, Hoskin DW, Bell JC, Johnston B, Pan C, Duncan R.

Mol Ther Oncolytics. 2017 Aug 4;6:80-89. doi: 10.1016/j.omto.2017.08.001. eCollection 2017 Sep 15.

22.

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.

Tong JG, Valdes YR, Sivapragasam M, Barrett JW, Bell JC, Stojdl D, DiMattia GE, Shepherd TG.

BMC Cancer. 2017 Aug 30;17(1):594. doi: 10.1186/s12885-017-3600-2.

23.

cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.

Ng KW, Marshall EA, Bell JC, Lam WL.

Trends Immunol. 2018 Jan;39(1):44-54. doi: 10.1016/j.it.2017.07.013. Epub 2017 Aug 19. Review.

PMID:
28830732
24.

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.

Bell JC, Ilkow CS.

Cancer Cell. 2017 Aug 14;32(2):133-134. doi: 10.1016/j.ccell.2017.07.012.

25.

RNA-dependent stabilization of SUV39H1 at constitutive heterochromatin.

Johnson WL, Yewdell WT, Bell JC, McNulty SM, Duda Z, O'Neill RJ, Sullivan BA, Straight AF.

Elife. 2017 Aug 1;6. pii: e25299. doi: 10.7554/eLife.25299.

26.

Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells.

Morettin A, Paris G, Bouzid Y, Baldwin RM, Falls TJ, Bell JC, Côté J.

Sci Rep. 2017 Jul 11;7(1):5153. doi: 10.1038/s41598-017-04955-4.

27.

Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.

Le Boeuf F, Selman M, Son HH, Bergeron A, Chen A, Tsang J, Butterwick D, Arulanandam R, Forbes NE, Tzelepis F, Bell JC, Werier J, Abdelbary H, Diallo JS.

Int J Cancer. 2017 Sep 15;141(6):1257-1264. doi: 10.1002/ijc.30813. Epub 2017 Jun 21.

28.

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE.

Oncoimmunology. 2017 Jan 31;6(4):e1285992. doi: 10.1080/2162402X.2017.1285992. eCollection 2017.

29.

Oncolytic Viruses: The Best is Yet to Come.

Lemay CG, Keller BA, Edge RE, Abei M, Bell JC.

Curr Cancer Drug Targets. 2018;18(2):109-123. doi: 10.2174/1568009617666170206111609.

PMID:
28176648
30.

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine.

Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang J, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB, Makrigiannis AP, Cron GO, Macdonald B, Marginean EC, Stojdl DF, Bell JC, Auer RC.

Cancer Immunol Res. 2017 Mar;5(3):211-221. doi: 10.1158/2326-6066.CIR-16-0162. Epub 2017 Feb 3.

31.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

32.

Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.

Wong CM, Nash LA, Del Papa J, Poulin KL, Falls T, Bell JC, Parks RJ.

Cancer Gene Ther. 2016 Oct;23(10):355-364. doi: 10.1038/cgt.2016.41. Epub 2016 Oct 14.

33.

Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.

Wang J, Arulanandam R, Wassenaar R, Falls T, Petryk J, Paget J, Garson K, Cemeus C, Vanderhyden BC, Wells RG, Bell JC, Le Boeuf F.

J Nucl Med. 2017 Feb;58(2):221-227. doi: 10.2967/jnumed.116.180463. Epub 2016 Sep 15.

34.

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells.

Corredor JC, Redding N, Bloté K, Robbins SM, Senger DL, Bell JC, Beaudry P.

Mol Ther Oncolytics. 2016 Mar 16;3:16005. doi: 10.1038/mto.2016.5. eCollection 2016.

35.

Single-particle characterization of oncolytic vaccinia virus by flow virometry.

Tang VA, Renner TM, Varette O, Le Boeuf F, Wang J, Diallo JS, Bell JC, Langlois MA.

Vaccine. 2016 Sep 30;34(42):5082-5089. doi: 10.1016/j.vaccine.2016.08.074. Epub 2016 Sep 8.

PMID:
27614781
36.

THE EFFICACY OF AN EIGHT-WEEK CORE STABILIZATION PROGRAM ON CORE MUSCLE FUNCTION AND ENDURANCE: A RANDOMIZED TRIAL.

Hoppes CW, Sperier AD, Hopkins CF, Griffiths BD, Principe MF, Schnall BL, Bell JC, Koppenhaver SL.

Int J Sports Phys Ther. 2016 Aug;11(4):507-19.

37.

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC.

Breast Cancer Res. 2016 Aug 8;18(1):83. doi: 10.1186/s13058-016-0744-y.

38.

School performance for children with cleft lip and palate: a population-based study.

Bell JC, Raynes-Greenow C, Turner R, Bower C, Dodson A, Nicholls W, Nassar N.

Child Care Health Dev. 2017 Mar;43(2):222-231. doi: 10.1111/cch.12388. Epub 2016 Aug 8.

PMID:
27502161
39.

Oncolytic viruses-immunotherapeutics on the rise.

Keller BA, Bell JC.

J Mol Med (Berl). 2016 Sep;94(9):979-91. doi: 10.1007/s00109-016-1453-9. Epub 2016 Aug 4. Review.

PMID:
27492706
40.

Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, de Souza CT, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 Jul 18;11(7):e0159471. doi: 10.1371/journal.pone.0159471. eCollection 2016.

41.

Oncolytic Viruses: Therapeutics With an Identity Crisis.

Breitbach CJ, Lichty BD, Bell JC.

EBioMedicine. 2016 Jul;9:31-36. doi: 10.1016/j.ebiom.2016.06.046. Epub 2016 Jul 2. Review.

42.

RecA: Regulation and Mechanism of a Molecular Search Engine: (Trends in Biochemical Sciences, June 2016, Vol. 41, No. 6, 491--507).

Bell JC, Kowalczykowski SC.

Trends Biochem Sci. 2016 Jul;41(7):646. doi: 10.1016/j.tibs.2016.05.006. Epub 2016 Jun 6. No abstract available.

PMID:
27283513
43.

First-in-class small molecule potentiators of cancer virotherapy.

Dornan MH, Krishnan R, Macklin AM, Selman M, El Sayes N, Son HH, Davis C, Chen A, Keillor K, Le PJ, Moi C, Ou P, Pardin C, Canez CR, Le Boeuf F, Bell JC, Smith JC, Diallo JS, Boddy CN.

Sci Rep. 2016 May 26;6:26786. doi: 10.1038/srep26786.

44.

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, Tanese de Souza C, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 May 19;11(5):e0155947. doi: 10.1371/journal.pone.0155947. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0159471.

45.

RecA: Regulation and Mechanism of a Molecular Search Engine.

Bell JC, Kowalczykowski SC.

Trends Biochem Sci. 2016 Jun;41(6):491-507. doi: 10.1016/j.tibs.2016.04.002. Epub 2016 May 4. Review. Erratum in: Trends Biochem Sci. 2016 Jul;41(7):646.

46.

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC.

Mol Ther Oncolytics. 2016 Feb 17;3:16001. doi: 10.1038/mto.2016.1. eCollection 2016.

47.

Mechanics and Single-Molecule Interrogation of DNA Recombination.

Bell JC, Kowalczykowski SC.

Annu Rev Biochem. 2016 Jun 2;85:193-226. doi: 10.1146/annurev-biochem-060614-034352. Epub 2016 Apr 18. Review.

PMID:
27088880
48.

Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC.

ILAR J. 2016;57(1):73-85. doi: 10.1093/ilar/ilv048.

49.

Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer.

Wong CM, Poulin KL, Tong G, Christou C, Kennedy MA, Falls T, Bell JC, Parks RJ.

PLoS One. 2016 Mar 17;11(3):e0151516. doi: 10.1371/journal.pone.0151516. eCollection 2016.

50.

Regulation of Macropinocytosis by Diacylglycerol Kinase ζ.

Ard R, Mulatz K, Pomoransky JL, Parks RJ, Trinkle-Mulcahy L, Bell JC, Gee SH.

PLoS One. 2015 Dec 23;10(12):e0144942. doi: 10.1371/journal.pone.0144942. eCollection 2015.

Supplemental Content

Support Center